FDA Armed And Ready For Next 'Pricing' Criticisms
This article was originally published in Scrip
Executive Summary
The next time lawmakers, as they inevitably will, want to blame the FDA for leaving patients with no options but to pay the hiked up prices of older pharmaceuticals because the agency has failed to move quicker on approving generic alternatives, regulators will be armed and ready with a new report, which shows they permitted more than 700 cheaper versions of brand-name medicines onto the US market in 2015 – more than ever before.